Publicado

2017-01-01

NLRP3 inflammasome: A therapeutic option for kidney disease?

El inflamasoma NLRP3: ¿Es realmente una opción terapéutica para la enfermedad renal?

Palabras clave:

Inflammation, inflammasomes, chronic renal diseases, hypertension, interleukins (en)
Inflamación, inflamasomas, insuficiencia renal crónica, interleucinas, hipertensión (es)

Descargas

Autores/as

  • Neudo Buelvas Jiménez Instituto Venezolano de Investigaciones Científicas (IVIC)
  • Raibel Janis Suárez Useche Instituto Venezolano de Investigaciones Científicas (IVIC)
  • José Ramón Vielma Guevara INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS

Objective To determine if considering inflammasome NLRP3 as a treatment option for kidney disease is possible.

Methods Literature review related to NLRP3 inflammasome structure, biological function and relationship with renal disease and others (hypertension, diabetes, gout, atherosclerosis, amyloidosis, Alzheimer's disease); the systematic review was made searching in the databases PubMed and SciELO for the following terms: "The NLRP3 inflammasome therapeutic for kidney disease", "NLRP3 nflammasome in kidney disease" in PubMed, and "Inflammasome" for Scielo.

Results 146 documents were found, althoughonly 34 matched the working hypothesis concerning the NLRP3 inflammasome as a central component of various diseases in humans, with potential therapeutic use. The NLRP3 inflammasome is responsible for the maturation of inflammatory pro-interleukin IL-1 β and IL-18, which can be triggered by aggregated or crystalline materials (particles), and by various microorganisms and toxins derived from these; however, the way how activation mechanisms work is not completely clear.

Conclusions Research on new therapies that focus on removing or inhibiting inflammasome components, both individually and together, is proposed.

Objetivo Determinar si el inflamasoma NLRP3 puede considerarse como opción de tratamiento para la enfermedad renal.

Métodos Con el fin de encontrar bibliografía relacionada con la estructura del inflamasoma NLRP3, su función biológica y su relación con la enfermedad renal y otras (hipertensión, diabetes, gota, aterosclerosis, amiloidosis, enfermedad de Alzheimer), se realizó una revisión sistemática en dos bases de datos (PubMed y SciELO) con los términos: "NLRP3 inflammasome therapeutic for kidney disease" y "NLRP3 inflammasome in kidney disease" en PubMed,  e "Iinflammasome" en SciELO.

Resultados Se encontró un total de 146 documentos, de los cuales solo 34 concuerdan con la hipótesis de trabajo desarrollada con relación al inflamasoma NLRP3 como componente central de diversas enfermedades en seres humanos y con potencial uso terapéutico. El inflamasoma NLRP3 es responsable de la maduración de la interleucina inflamatoria pro-IL-1 β y IL-18, l cual puede darse por causa de materiales agregados o cristalinos (partículas), y por diversos microorganismos y toxinas derivadas de los mismos; sin embargo, los mecanismos de activación de este proceso siguen sin ser claros en la actualidad.

Conclusiones Se propone estudiar nuevas terapias que se centren en la eliminación o inhibición de los componentes inflamasoma, de manera individual y conjunta.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Rodríguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson RJ. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012; 39 (1): 96-103. http://www.ncbi.nlm.nih.gov/pubmed/21251049.

Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant. 2014; 29 (1): 41-48. http://www.ncbi.nlm.nih.gov/pubmed/24026244.

Pons H, Ferrebuz A, Quiroz Y, Romero-Vásquez F, Parra G, Johnson RJ, et al. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Renal Physiol. 2013; 304 (3): F289-299. http://www.ncbi.nlm.nih.gov/pubmed/23097471.

Newton K, Dixit VM. Signaling in Innate Immunity and Inflammation. Cold Spring Harb Perspect Biol. 2012; 4 (3): 1-19.

http://www.ncbi.nlm.nih.gov/pubmed/22296764.

Suárez R, Buelvas N. El inflamasoma: mecanismos de activación. Invest Clin. 2015; 56 (1): 74-99. http://www.ncbi.nlm.nih.gov/pubmed/25920188.

Buelvas-Jiménez N, Suárez-Useche R. Regulación del inflamasoma: bioquímica y más allá de ella. IATREIA. 2015; 28 (2): 170-180.

http://www.scielo.org.co/pdf/iat/v28n2/v28n2a07.pdf

Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S, et al. NLRC4-driven interleukin-1β production discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol. 2012; 13 (5): 449-456. http://www.ncbi.nlm.nih.gov/pubmed/22484733.

Esser N, Legrand S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014; 105 (2): 141-150. http://www.ncbi.nlm.nih.gov/pubmed/24798950.

Andersen K, Eltrich N, Lichtnekert J, Anders HJ, Vielhauer V. The NLRP3/ASC inflammasome promotes T-cell-dependent immune complex glomerulonephritis by canonical and noncanonical mechanisms. Kidney Int. 2014; 86 (5): 965-978. http://www.ncbi.nlm.nih.gov/pubmed/24805106.

Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem. 2012; 287 (50): 41732-41743.

http://www.ncbi.nlm.nih.gov/pubmed/23066025.

Halff E, Diebolder C, Versteeg M, Schouten A, Brondijk H, Huizinga E. Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved n- and c-terminal regions of flagellin. J Biol Chem. 2012; 287 (46): 38460-38472. http://www.ncbi.nlm.nih.gov/pubmed/23012363.

Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol. 2003; 4 (2): 95-104.

http://www.ncbi.nlm.nih.gov/pubmed/12563287.

Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell. 2013; 49 (2): 331-338. http://www.ncbi.nlm.nih.gov/pubmed/23246432.

Anders HJ, Muruve DA. The Inflammasomes in Kidney Disease. J Am Soc Nephrol. 2011; 22 (6): 1007-1018. http://www.ncbi.nlm.nih.gov/pubmed/21566058.

Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther. 2013; 15 (1):1-8. http://www.ncbi.nlm.nih.gov/pubmed/23442610.

Kang SJ, Wang S, Kuida K, Yuan J. Distinct downstream pathways of caspase-11 in regulating apoptosis and cytokine maturation during septic schock response. Cell Death Differ. 2002; 9 (10): 1115-1125.

http://www.ncbi.nlm.nih.gov/pubmed/12232800.

Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep. 2011; 13 (2): 160-166. http://www.ncbi.nlm.nih.gov/pubmed/21234729.

Lee H, Kim J, Kim H, Shong M, Ku B, Jo E. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. 2013; 62 (1): 194-204. http://www.ncbi.nlm.nih.gov/pubmed/23086037.

De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011; 32 (8): 373-379.

http://www.ncbi.nlm.nih.gov/pubmed/21733753.

Strowig T, Henao J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012; 481 (7381): 278-286.

http://www.ncbi.nlm.nih.gov/pubmed/22258606.

Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, et al. Association between the interleukin-1beta polymorphisms and Alzheimer’s disease: a systematic review and meta-analysis. Brain Res Rev. 2008; 59 (1): 155-163. http://www.ncbi.nlm.nih.gov/pubmed/22356904.

Bakker PJ, Butter LM, Kors L, Teske GJ, Aten J, Sutterwala FS, et al. Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation. Kidney Int. 2014; 85 (5): 1112-1122.

http://www.ncbi.nlm.nih.gov/pubmed/24352154.

Rodríguez-Iturbe B, Pons H, Quiroz Y, Lanaspa MA, Johnson RJ. Autoimmunity in the pathogenesis of hypertension. Nature Rev Nephrol. 2014; 10 (1): 56-62. http://www.ncbi.nlm.nih.gov/pubmed/24247285.

Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signaling pathways on ROS production? Nature Rev Immunol. 2010; 10 (3): 210-215. http://www.ncbi.nlm.nih.gov/pubmed/20168318.

Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 Inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014; 59 (3): 898-910. http://www.ncbi.nlm.nih.gov/pubmed/23813842.

Subramanian N, Natarajan K, Clatworthy MR, Wang Z, Germain RN. The adapter MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell. 2013; 153 (2): 348-361.

http://www.ncbi.nlm.nih.gov/pubmed/23582325.

Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat immunol. 2015; 16 (8): 859-870. http://www.ncbi.nlm.nih.gov/pubmed/26098997.

Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010; 285 (13): 9792-9802. http://www.ncbi.nlm.nih.gov/pubmed/20093358.

He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014; 289 (2):1142-1150. http://www.ncbi.nlm.nih.gov/pubmed/24265316.

Ahn H, Kim J, Jeung EB, Lee GS. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology. 2014; 219 (4): 315-322. http://www.ncbi.nlm.nih.gov/pubmed/24380723.

Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21 (3): 248-255. http://www.ncbi.nlm.nih.gov/pubmed/25686105.

Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, et al. Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol. 2015; 173 (4): 752-765. http://www.ncbi.nlm.nih.gov/pubmed/26103560.

Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015; 21 (3): 263-269. http://www.ncbi.nlm.nih.gov/pubmed/25686106.

Levy M, Thaiss CA, Elinav E. Taming the inflammasome. Nat Med. 2015; 21 (3): 213-215. http://www.ncbi.nlm.nih.gov/pubmed/25742454.

Licencia

Derechos de autor 2017 Revista de Salud Pública

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Esta revista provee acceso libre inmediato a su contenido bajo el principio de que hacer disponible gratuitamente investigación al publico apoya a un mayor intercambio de conocimiento global.

Todos los contenidos de esta revista, excepto dónde está identificado, están publicados bajo una Licencia Creative Commons Atribución 4.0.